<DOC>
	<DOCNO>NCT00112996</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Chemoprotective drug , alpha-lipoic acid , may protect normal cell side effect chemotherapy . Alpha-lipoic acid may also prevent damage nerve carry information brain spinal cord rest body . It know whether alpha-lipoic acid effective placebo prevent peripheral neuropathy . PURPOSE : This randomized phase III trial study alpha-lipoic acid see well work compare placebo prevent peripheral neuropathy patient receive chemotherapy cancer .</brief_summary>
	<brief_title>Alpha-Lipoic Acid Preventing Peripheral Neuropathy Patients Receiving Chemotherapy Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare whether treatment alpha-lipoic acid v placebo decrease severity frequency peripheral neuropathy cancer patient receive cisplatin- oxaliplatin-containing chemotherapy regimen . - Compare protective effect duration drug patient . Secondary - Determine large sensory fiber integrity associate platinum-induced peripheral neuropathy , measure three time functional test comprise fasten 6-buttons , walk 50 foot , place coin cup , patient treat drug . - Compare number chemotherapy course dos receive patient treat drug . Tertiary - Compare optimal tumor response ( disease progression , stable disease , partial response , complete response ) chemotherapy patient treat drug . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord prior platinum-containing treatment ( yes v ) . Patients receive prior treatment stratify accord prior cumulative platinum exposure ( cisplatin &lt; 200 mg/m^2 oxaliplatin &lt; 750 mg/m^2 v cisplatin 200-399 mg/m^2 oxaliplatin 750-999 mg/m^2 v cisplatin &gt; 400 mg/m^2 oxaliplatin &gt; 1,000 mg/m^2 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral alpha-lipoic acid* three time daily least 24 week absence unacceptable toxicity . - Arm II : Patients receive oral placebo* three time daily least 24 week absence unacceptable toxicity . NOTE : *In arm , patient begin take study drug 4 day completion chemotherapy treatment continue take study drug 2 day next schedule chemotherapy treatment . Patients ' symptom peripheral neuropathy , pain , functional test assess baseline week 6-8 , 12 , 24 , 36 , 48 . PROJECTED ACCRUAL : A total 244 patient ( 122 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Scheduled receive cisplatin oxaliplatincontaining chemotherapy regimen cancer No establish clinical neuropathy No clinically evident CNS metastasis , include leptomeningeal metastasis PATIENT CHARACTERISTICS : Age Not specify Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin &lt; 2 mg/dL Renal Creatinine &lt; 2 mg/dL OR Creatinine clearance &gt; 45 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Must normal state arousal No confusion memory concentration deficit No history diabetes mellitus require oral medication insulin treatment No chronic alcoholism No active central nervous system ( CNS ) disease ( e.g. , dementia encephalopathy ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No carboplatin , vincristine , vinblastine , paclitaxel , docetaxel 6 month prior , , 6 month study treatment Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Concurrent medication modify peripheral neuropathy ( e.g. , gabapentin , lamotrigine , carbamazepine , phenytoin , tricyclic antidepressant ) allow provide dose adjustment within 2 week study entry study participation No concurrent vitamin E ( include multivitamin contain vitamin E ) â‰¥ 100 IU per day No concurrent physical modality ( e.g. , anodyne [ monochromatic nearinfrared photoenergy , 890 nm ] , microcurrent , transcutaneous electrical neural stimulation ) peripheral neuropathy relate symptom unless physical occupational therapy functional training</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>